These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20392250)

  • 21. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis.
    Bamias G; Siakavellas SI; Stamatelopoulos KS; Chryssochoou E; Papamichael C; Sfikakis PP
    Clin Immunol; 2008 Nov; 129(2):249-55. PubMed ID: 18757243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decoy receptor 3 ameliorates an autoimmune crescentic glomerulonephritis model in mice.
    Ka SM; Sytwu HK; Chang DM; Hsieh SL; Tsai PY; Chen A
    J Am Soc Nephrol; 2007 Sep; 18(9):2473-85. PubMed ID: 17687076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New potential targets for treating myeloma bone disease.
    Roodman GD
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenesis and management of myeloma bone disease.
    Christoulas D; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus-like syndrome.
    Han B; Moore PA; Wu J; Luo H
    Arthritis Rheum; 2007 Nov; 56(11):3748-58. PubMed ID: 17968950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6.
    Hongming H; Jian H
    Leuk Res; 2009 Jan; 33(1):115-22. PubMed ID: 18778854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.
    Kindle L; Rothe L; Kriss M; Osdoby P; Collin-Osdoby P
    J Bone Miner Res; 2006 Feb; 21(2):193-206. PubMed ID: 16418775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
    Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
    Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages.
    Tai SK; Chang HC; Lan KL; Lee CT; Yang CY; Chen NJ; Chou TY; Tarng DC; Hsieh SL
    J Immunol; 2012 Mar; 188(5):2464-71. PubMed ID: 22287720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
    Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis of myeloma bone disease.
    Roodman GD
    Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DcR3 protects islet beta cells from apoptosis through modulating Adcyap1 and Bank1 expression.
    Han B; Wu J
    J Immunol; 2009 Dec; 183(12):8157-66. PubMed ID: 20007581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
    Chang PM; Chen PM; Hsieh SL; Tzeng CH; Liu JH; Chiou TJ; Wang WS; Yen CC; Gau JP; Yang MH
    Int J Oncol; 2008 Sep; 33(3):549-54. PubMed ID: 18695885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sclerostin is overexpressed by plasma cells from multiple myeloma patients.
    Brunetti G; Oranger A; Mori G; Specchia G; Rinaldi E; Curci P; Zallone A; Rizzi R; Grano M; Colucci S
    Ann N Y Acad Sci; 2011 Nov; 1237():19-23. PubMed ID: 22082361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Myeloma bone disease].
    Abe M
    Clin Calcium; 2014 Aug; 24(8):1159-68. PubMed ID: 25065867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.